Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

1

Patients with hematologic malignancies have lower seroconversion rates after SARS-CoV-2 vaccination compared to solid cancer patients.
2

Approximately two-thirds of hematologic malignancy patients achieved anti-spike IgG seroconversion after complete vaccination.
3

Cell-mediated immune responses may improve survival in hematologic malignancy patients despite impaired humoral immunity.
4

The effectiveness of booster doses in enhancing seroconversion rates in hematologic malignancy patients remains largely undefined.
5

This meta-analysis aims to assess immunogenicity and factors influencing immune responses following SARS-CoV-2 vaccination in hematologic malignancies.

Blood Cancer Journal

by Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, Thita Chiasakul, Ponlapat Rojnuckarin
December 23, 2022

1